B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® (FOTO)

MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J. (ots) - Joint marketing of
CytoSorb® with B. Braun's newest OMNI® blood purification platform will offer
greater access of this advanced treatment of deadly inflammation to critically
ill patients.

B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical
products and services and CytoSorbents Corporation (NASDAQ: CTSO),a critical
care immunotherapy leader commercializing its CytoSorb® blood purification
technology to treat deadly inflammation, announce the launch of a global
co-marketing agreement to promote the use of CytoSorb® with B. Braun's latest
OMNI® continuous blood purification platform and OMNIset® Plus bloodline set
(set version 3.0 or higher).

The CytoSorb® adsorber is used in critical care for the extracorporeal removal
of cytokines and inflammatory mediatorsfrom the bloodstream and can be operated
with the B. Braun OMNI® acute dialysis machine. B. Braun will supply the market
with the OMNI® and OMNIset® Plus while CytoSorbents and its network of direct
sales, strategic partners, and distributors will continue to supply the market
with CytoSorb®. CytoSorb® is CE Mark certified and distributed in 67 countries
worldwide.

Dr. Holger Seeberg, Member of the Management Board of B. Braun Avitum commented,
"We are excited to announce this co-marketing agreement with CytoSorbents.
Through this collaboration, we want to provide physicians and medical centers
with one of the most promising ways to control deadly inflammation with one of
the most capable blood purification platforms available in critical care today."

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "We are
delighted to add B. Braun, a trusted global organization and leading player in
renal replacement therapy and intensive care medicine, to the CytoSorbents
partner network. B. Braun's OMNI® platform is an elegant and powerful machine,
providing physicians the flexibility to use CytoSorb® to treat patients
suffering from a wide range of deadly conditions in the intensive care unit."

Mr. Chris Cramer, Vice President of Business Development at CytoSorbents added,
"We are very excited to begin this new partnership with B. Braun, a world class
company. We believe there are many synergies to this partnership and we plan to
work closely with B. Braun's global commercial organization to expand the
combined use of CytoSorb®, a leading treatment of cytokine storm, with B.
Braun's latest extracorporeal platform, the OMNI® and OMNIset® Plus bloodline